Sign In
Buy BIIB
$207.94
+1.66 (+0.80%)
At Close: Aug 07, 2026
The 3 Most Promising Biotech Innovations in 2023 and the Stocks to Buy
06:26am, Friday, 28'th Apr 2023
The biotech sector is up 4.76% so far in 2023. This continues the nice run that biotech stocks had in 2022.
FDA grants accelerated approval to Biogen's treatment for rare form of ALS
01:52pm, Tuesday, 25'th Apr 2023
The U.S. Food and Drug Administration said Tuesday it has granted accelerated approval to Biogen Inc.'s BIIB torferson, a treatment for a rare form of amyotrophic lateral sclerosis, or ALS. The accele
Biogen isn't concerned about competing with Eli Lilly in the Alzheimer's drug space, CEO says
01:40pm, Tuesday, 25'th Apr 2023
Biogen CEO Christopher Viehbacher said during an earnings call that Eli Lilly needs to consider maintenance doses its Alzheimer's treatment donanemab.
FDA grants accelerated approval for Biogen ALS drug that treats rare form of the disease
01:20pm, Tuesday, 25'th Apr 2023
The FDA's approval requires Biogen to further study its ALS drug tofersen to further verify its clinical benefits.
Biogen (BIIB) Beats on Q1 Earnings, Ends Some Research Programs
12:57pm, Tuesday, 25'th Apr 2023
Biogen (BIIB) beats first-quarter estimates for earnings and sales. It maintains its 2023 guidance.
Biogen Inc. (BIIB) Q1 2023 Earnings Call Transcript
12:37pm, Tuesday, 25'th Apr 2023
Biogen Inc. (BIIB) Q1 2023 Earnings Call Transcript.
Biogen Inc. (BIIB) Beats Q1 Earnings and Revenue Estimates
09:53am, Tuesday, 25'th Apr 2023
Biogen Inc. (BIIB) came out with quarterly earnings of $3.40 per share, beating the Zacks Consensus Estimate of $3.25 per share. This compares to earnings of $3.62 per share a year ago.
Alzheimer's Drugs Still Aren't Biogen's Saving Grace — But The Company Is Hopeful
08:58am, Tuesday, 25'th Apr 2023
Biogen stock fell early Tuesday as the company reiterated its outlook for declining sales despite its new Alzheimer's treatment. The post Alzheimer's Drugs Still Aren't Biogen's Saving Grace — But T
Biogen tops estimates as revenue slides 3% from a year ago
07:25am, Tuesday, 25'th Apr 2023
Biogen Inc. BIIB said Tuesday it had net income of $387.9 million, or $2.67 a share, for the first quarter, up from $303.8 million, or $2.06 a share, in the year-earlier period. Adjusted per-share ear
Better Big Biotech Buy: Biogen vs. Vertex
02:00pm, Thursday, 20'th Apr 2023
Biogen and Vertex are both waiting on big regulatory decisions for potential products. The companies each bring in billions of dollars in revenue every year.
Biogen (BIIB) to Report Q1 Earnings: Here's What to Expect
12:10pm, Wednesday, 19'th Apr 2023
Biogen's (BIIB) sales in the first quarter are likely to have been hurt by lower sales of multiple sclerosis drugs, while sales of Spinraza are likely to have improved.
Earnings Preview: Biogen Inc. (BIIB) Q1 Earnings Expected to Decline
11:26am, Tuesday, 18'th Apr 2023
Biogen Inc. (BIIB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is Biogen Stock a Buy Now?
09:53am, Tuesday, 18'th Apr 2023
Biogen could be close to a game-changing approval for an Alzheimer's medicine. This therapy would help significantly improve the biotech's financial results.
Bulls Blast Biotech Stock Before Earnings
10:14am, Monday, 17'th Apr 2023
Biogen Inc (NASDAQ:BIIB) is buzzing today, after Piper Sandler and Wedbush praised the drugmaker ahead of the company's first-quarter earnings report -- due out before the market's open on Tuesday,
Alzheimer's patients retain the benefits of Leqembi even when they stop the drug, Eisai says
06:26pm, Thursday, 06'th Apr 2023
Alzheimer's patients who take Leqembi retain the benefits of the treatment even when they stop taking it, new research by Eisai and Biogen shows.
